Cost-effectiveness of nab-paclitaxel plus gemcitabine versus erlotinib plus gemcitabine in metastatic pancreatic cancer

被引：2
|
作者：
Chiorean, E. Gabriela
Whiting, Scott
Binder, Gary
Dranitsaris, George
Manax, Victoria
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Celgene Corp, Summit, NJ USA
[3] Augmentium Pharma Consulting, Toronto, ON, Canada
[4] Celgene, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.353
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
353
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer
    Martina Catalano
    Giuseppe Aprile
    Raffaele Conca
    Roberto Petrioli
    Monica Ramello
    Giandomenico Roviello
    Scientific Reports, 12
  • [32] The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer
    Catalano, Martina
    Aprile, Giuseppe
    Conca, Raffaele
    Petrioli, Roberto
    Ramello, Monica
    Roviello, Giandomenico
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [33] Effectiveness of CA 19.9 in predicting prognosis in metastatic pancreatic cancer patients treated with nab-paclitaxel plus gemcitabine
    Mariani, S.
    Soro, P.
    Liscia, N.
    Balconi, F.
    Camera, S.
    Donisi, C.
    Impera, V.
    Musio, F.
    Persano, M.
    Pireddu, A.
    Pretta, A.
    Tolu, S.
    Pusceddu, V.
    Lai, E.
    Faloppi, L.
    Demurtas, L.
    Ziranu, P.
    Puzzoni, M.
    Scartozzi, M.
    ANNALS OF ONCOLOGY, 2019, 30 : 63 - 63
  • [34] A COST-UTILITY ANALYSIS OF NAB-PACLITAXEL (ABRAXANE) PLUS GEMCITABINE IN METASTATIC PANCREATIC CANCER IN SLOVAK REPUBLIC
    Stetka, R.
    Ondrusova, M.
    Psenkova, M.
    Pastorek, T.
    Salek, T.
    VALUE IN HEALTH, 2015, 18 (07) : A464 - A464
  • [35] A Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Advanced Pancreatic Cancer Refractory to Gemcitabine Monotherapy
    Nishioka, Mariko
    Okano, Naohiro
    Wakabayashi, Masashi
    Ikeno, Takashi
    Hayashi, Masato
    Mizutani, Tomonori
    Nagashima, Fumio
    Furuse, Junji
    ANTICANCER RESEARCH, 2024, 44 (03) : 1233 - 1239
  • [36] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Yasin
    Karhan, Ogur
    Aldemir, Mehmet Naci
    Urun, Muslih
    Ercek, Berrak Mermit
    Urakci, Zuhat
    Arvas, Hayati
    Tunc, Sezai
    Erdem, Mehmet
    Yerlikaya, Halis
    Ileri, Serdar
    Aydin, Ibrahim
    Bicer, Abdurrahman
    Komuroglu, Ahmet Ufuk
    Majidova, Nargiz
    Gokcek, Savas
    Demir, Hacer
    Yildiz, Sedat
    Akbas, Sinem
    Ozen, Esra
    Kahya, Burcu Ulas
    Sali, Muersel
    Anik, Hicran
    Aykut, Talat
    Araz, Murat
    Alkan, Ali
    Ozcelik, Melike
    Sakin, Abudllah
    Aykan, Musa Baris
    Mehtiyev, Mirmehdi
    Demir, Bilgin
    Baser, Mehmet Nuri
    Sonmez, Muge
    Gulturk, Ilkay
    Avci, Niluever
    Urvay, Semiha
    Arici, Mustafa Ozgur
    Kalender, Mehmet Emin
    Yildirim, Mustafa
    Solmaz, Ali Alper
    Gurbuz, Mustafa
    Ergun, Yakup
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [37] Efficacy of gemcitabine plus nab-paclitaxel in second-line treatment of metastatic pancreatic cancer
    Sezgin, Y.
    Karhan, O.
    Urakci, Z.
    Mecidova, N.
    Araz, M.
    Sakin, A.
    Ercek, B. M.
    Urun, M.
    Urvay, S.
    Aykan, M. B.
    Kocak, S.
    Arici, M. O.
    Avci, N.
    Alkan, A.
    Ozcelik, M.
    Aldemir, M. N.
    Ergun, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S930 - S930
  • [38] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    E Gabriela Chiorean
    Daniel D Von Hoff
    Josep Tabernero
    Robert El-Maraghi
    Wen Wee Ma
    Michele Reni
    Marion Harris
    Robert Whorf
    Helen Liu
    Jack Shiansong Li
    Victoria Manax
    Alfredo Romano
    Brian Lu
    David Goldstein
    British Journal of Cancer, 2016, 115 : 188 - 194
  • [39] Gemcitabine plus nab-paclitaxel use in metastatic pancreatic cancer: A study of 40 patients.
    Barrera, Ivan
    Filimon, Sabin Dragos
    Meng, Jassy
    Kavan, Tomas
    Rho, Young Soo
    Batist, Gerald
    Kavan, Petr
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [40] Second-line therapy after nab-paclitaxel plus gemcitabine or after gemcitabine for patients with metastatic pancreatic cancer
    Chiorean, E. Gabriela
    Von Hoff, Daniel D.
    Tabernero, Josep
    El-Maraghi, Robert
    Ma, Wen Wee
    Reni, Michele
    Harris, Marion
    Whorf, Robert
    Liu, Helen
    Li, Jack Shiansong
    Manax, Victoria
    Romano, Alfredo
    Lu, Brian
    Goldstein, David
    BRITISH JOURNAL OF CANCER, 2016, 115 (02) : 188 - 194
12345